By David Cassak and Stephen Levin
After dropping markedly for two consecutive years, both the number of acquisitions in medical devices and the total dollar volume...
In Device M&A, Happy Days are Here Again
After dropping markedly for two consecutive years, both the number of acquisitions in medical devices and the total dollar volume of those deals jumped significantly in 2003, reaching 71 and $9.17 billion, respectively. And if the dollar volumes and number of deals in 2003 weren't good news enough, an analysis of some of the trends behind the deal-making should give device executives even more cause to be happy. Thus, while a significant number of the total deals do fall within only two clinical categories, cardiovascular and orthopedics, the larger picture shows an M&A climate that is quite diversified. Similarly, the perception that deal-making is concentrated in the hands of a small group of large companies isn't borne out by the data. That said, new technology trends, most notably the convergence of drugs and devices, and new deal structures suggest, at least anecdotally, that device M&A may be changing.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.